After the company announced 510(k) approval of its next-generation radiation therapy system and provided investors with a few financial highlights, shares of ViewRay, Inc. (NASDAQ: VRAY) rose by 24% as of 3:15 p.m. EST on Monday.
ViewRay announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its next-generation MRIdian Linac system. The company believes that this new product will enable oncologists to watch how the body reacts to radiation therapy in real time, allowing them to make therapy adjustments on the fly.